1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Endocrine Therapy 2: new trials by email Literature Review of Endocrine Therapy 2 trials Research Report on Endocrine Therapy 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PF-06873600 in People With Cancer PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2 - HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer | Phase 1 / Phase 2 | Terminated | Pfizer | 155 | 2018-03-07 | 2025-11-14 |
Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Pfizer (1)
Bulgaria (1) · Canada (1) · Japan (1) · Russia (1) · Ukraine (1) · United States (1)